IL285999B2 - JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction - Google Patents

JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction

Info

Publication number
IL285999B2
IL285999B2 IL285999A IL28599921A IL285999B2 IL 285999 B2 IL285999 B2 IL 285999B2 IL 285999 A IL285999 A IL 285999A IL 28599921 A IL28599921 A IL 28599921A IL 285999 B2 IL285999 B2 IL 285999B2
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
acceptable salt
pathway inhibitor
jak1 pathway
subject
Prior art date
Application number
IL285999A
Other languages
English (en)
Hebrew (he)
Other versions
IL285999B1 (en
IL285999A (en
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of IL285999A publication Critical patent/IL285999A/en
Publication of IL285999B1 publication Critical patent/IL285999B1/en
Publication of IL285999B2 publication Critical patent/IL285999B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL285999A 2019-03-05 2020-03-05 JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction IL285999B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814085P 2019-03-05 2019-03-05
PCT/US2020/021088 WO2020181034A1 (en) 2019-03-05 2020-03-05 Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction

Publications (3)

Publication Number Publication Date
IL285999A IL285999A (en) 2021-10-31
IL285999B1 IL285999B1 (en) 2025-09-01
IL285999B2 true IL285999B2 (en) 2026-01-01

Family

ID=69941525

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285999A IL285999B2 (en) 2019-03-05 2020-03-05 JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction

Country Status (15)

Country Link
US (2) US11406640B2 (https=)
EP (2) EP3934651A1 (https=)
JP (2) JP2022524997A (https=)
KR (1) KR20210137087A (https=)
CN (1) CN114007621A (https=)
AU (1) AU2020232757B2 (https=)
CA (1) CA3132371A1 (https=)
EA (1) EA202192426A1 (https=)
IL (1) IL285999B2 (https=)
MA (1) MA55201A (https=)
MX (2) MX2021010545A (https=)
PH (1) PH12021552130A1 (https=)
SG (1) SG11202109563WA (https=)
UA (1) UA130579C2 (https=)
WO (1) WO2020181034A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3837258T (pt) 2018-09-04 2024-06-20 Theravance Biopharma R&D Ip Llc Amidas de dimetil amino azetidina como inibidores de jak
WO2020051139A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as jak inhibitors
MX2021004582A (es) 2018-10-29 2021-06-15 Theravance Biopharma R&D Ip Llc Compuesto 2-azabiciclo hexano inhibidor de jak.
CA3117969A1 (en) 2018-10-31 2020-05-07 Incyte Corporation Combination therapy for treatment of hematological diseases
MA55201A (fr) * 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP4274578A1 (en) * 2021-01-11 2023-11-15 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
KR102952944B1 (ko) 2021-10-15 2026-04-14 주식회사 엘지에너지솔루션 용접봉 체결 방법 및 이에 의해 용접봉이 수직으로 체결된 용접 장치

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021153A1 (en) * 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
WO2015131031A1 (en) * 2014-02-28 2015-09-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
WO2018099680A1 (en) * 2016-11-29 2018-06-07 Sandoz Ag Citrate salts of a janus kinase (jak) inhibitor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US20070219223A1 (en) 2006-03-07 2007-09-20 Endacea, Inc. Compositions and methods for treating respiratory disorders
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
EP2684564A1 (en) 2008-04-17 2014-01-15 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PE20121336A1 (es) 2009-12-01 2012-11-03 Abbvie Inc Nuevos compuestos triciclicos
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AU2013274030B2 (en) 2012-06-15 2016-07-07 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
CA2880083A1 (en) 2012-08-17 2014-02-20 Concert Pharmaceuticals, Inc. Deuterated baricitinib
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
SMT201900223T1 (it) 2013-05-17 2019-07-11 Incyte Corp Sale di bipirazolo come inibitore di jak
EP3060234A1 (en) * 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
CN106687462A (zh) 2014-04-30 2017-05-17 因赛特公司 Jak1抑制剂的制备方法以及其新形式
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
HK1252685A1 (zh) 2015-11-03 2019-05-31 Theravance Biopharma R&D Ip, Llc 用於治疗呼吸疾病的jak激酶抑制剂化合物
CN105294699B (zh) * 2015-12-04 2019-06-11 上海勋和医药科技有限公司 巴瑞替尼的制备方法
KR102399848B1 (ko) * 2016-10-03 2022-05-19 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 신규한 jak1 선택적 억제제 및 그 용도
BR112019018648A2 (pt) 2017-03-09 2020-06-16 Theravance Biopharma R&D Ip, Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
US10406148B2 (en) 2017-05-01 2019-09-10 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
IL311485B1 (en) 2018-02-16 2026-01-01 Incyte Corp JAK1 pathway inhibitors for the treatment of cytokine-related disorders
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
CA3097025A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
CA3117969A1 (en) 2018-10-31 2020-05-07 Incyte Corporation Combination therapy for treatment of hematological diseases
CA3123596A1 (en) 2018-12-19 2020-06-25 Incyte Corporation Jak1 pathway inhibitors for the treatment of gastrointestinal disease
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021153A1 (en) * 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
WO2015131031A1 (en) * 2014-02-28 2015-09-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
WO2018099680A1 (en) * 2016-11-29 2018-06-07 Sandoz Ag Citrate salts of a janus kinase (jak) inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOETTLER MICHELLE ET AL,, RUXOLITINIB IS AN EFFECTIVE STEROID SPARING AGENT IN CHILDREN WITH STEROID REFRACTORY/DEPENDENT BRONCHIOLITIS OBLITERANS SYNDROME AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION, 25 January 2019 (2019-01-25) *
GOROSPE SARASUA L ET AL,, RADIOLOGICAL IMPROVEMENT OF BRONCHIOLITIS OBLITERANS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT TREATED WITH RUXOLITINIB, 1 December 2018 (2018-12-01) *
SCHOETTLER MICHELLE ET AL,, RUXOLITINIB AND STEROID REFRACTORY/DEPENDENT BRONCHIOLITIS OBLITERANS AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STEROID SPARING AGENT THAT ALSO RESULTED IN IMPROVED LUNG FUNCTION IN CHILDREN, 29 November 2018 (2018-11-29) *

Also Published As

Publication number Publication date
AU2020232757A1 (en) 2021-10-07
EP4691567A3 (en) 2026-04-29
WO2020181034A1 (en) 2020-09-10
JP2022524997A (ja) 2022-05-11
CN114007621A (zh) 2022-02-01
MX2024007081A (es) 2024-06-21
MA55201A (fr) 2022-01-12
SG11202109563WA (en) 2021-09-29
EP3934651A1 (en) 2022-01-12
IL285999B1 (en) 2025-09-01
CA3132371A1 (en) 2020-09-10
PH12021552130A1 (en) 2022-08-31
KR20210137087A (ko) 2021-11-17
EP4691567A2 (en) 2026-02-11
UA130579C2 (uk) 2026-03-25
US20220331325A1 (en) 2022-10-20
MX2021010545A (es) 2021-11-17
IL285999A (en) 2021-10-31
US11406640B2 (en) 2022-08-09
JP2025087734A (ja) 2025-06-10
US20200281931A1 (en) 2020-09-10
EA202192426A1 (ru) 2021-11-15
US11896595B2 (en) 2024-02-13
AU2020232757B2 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
US11896595B2 (en) JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
TWI835786B (zh) 使用ｊａｋ抑制劑治療化膿性汗腺炎
CA3158254C (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
KR20150038486A (ko) 중수소화된 아이브루티닙
WO2019224773A1 (en) Heterocyclic amides as rip1 kinase inhibitors
TW202039459A (zh) Alk5 抑制劑
US20240293411A1 (en) Combination therapy comprising jak pathway inhibitor and rock inhibitor
EA044660B1 (ru) Ингибиторы путей jak1 для лечения хронической дисфункции аллотрансплантата легких
US20240058343A1 (en) Treatment of urticaria using jak inhibitors
EA050167B1 (ru) Комбинированная терапия, включающая ингибитор пути jak и ингибитор rock
HK40122816A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
EA045057B1 (ru) Лечение b-клеточных злокачественных новообразований с применением комбинации ингибиторов jak и pi3k